secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGILE THERAPEUTICS INC (—)
CIK:        0001261249
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001558370-24-004174
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agile Therapeutics FY2023 rev $19.6M (+80% YoY); GAAP net loss $14.5M; Nasdaq delisted; debt paid
--------------------------------------------------------------------------------

- Full year 2023 net revenue $19.6M, up 80% YoY; Twirla demand up 131% to 243,841 cycles.
- GAAP net loss $14.5M ($6.71/share); non-GAAP net loss $21.2M ($9.84/share); OPEX down 33% to $30.5M.
- Cash $2.5M at Dec 31, 2023; raised $4.8M via warrant exercise in Feb 2024; paid off Perceptive Advisors debt in Q1 2024.
- Delisted from Nasdaq on Mar 25; now trading on OTC under AGRX; does not expect impact on business.
- Twirla demand rebounding in Q1 2024; January retail cycles (26,464) highest single month since launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1261249/000155837024004174/0001558370-24-004174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1261249/000155837024004174/agrx-20240328x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-004174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer